Metallodrug conjugates with steroids and selective estrogen receptor modulators (SERM)

Current Medicinal Chemistry

Volumn 16, Issue 18, 2009, Pages 2324-2337

  Biersack, B ^a   Schobert, Rainier ^a  

^a UNIVERSITY OF BAYREUTH   (Germany)

Author keywords

Anticancer drugs; Estrogen receptor; Selective steroid receptor modulators; Steroids; Targeted metallodrugs

Indexed keywords

1,2 DIAMINOCYCLOHEXANE PLATINUM (II); ANTINEOPLASTIC AGENT; CISPLATIN; CONJUGATED ESTROGEN; CYCLIC AMP DEPENDENT PROTEIN KINASE; DICHLORO(3 O ESTRADIOL 6 AMINOMETHYLNICOTINATE)PLATINUM (II); ESTRADIOL; GENISTEIN; GPR 30; INDAZOLIUM TETRACHLOROBIS(INDAZOLE)RUTHENATE; PLATINUM ESTROGEN CONJUGATE; PROGESTERONE RECEPTOR; PROTEIN KINASE C; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SEX HORMONE BINDING GLOBULIN; STEROID; STEROID METALLODRUG CONJUGATE; STEROID RECEPTOR; TAMOXIFEN; UNCLASSIFIED DRUG; ESTROGEN RECEPTOR; ORGANOMETALLIC COMPOUND;

ALKYLATION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BINDING AFFINITY; CANCER CELL; CANCER INHIBITION; CELL PROLIFERATION; CYTOTOXICITY; DNA BINDING; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG STRUCTURE; HUMAN; HYDROLYSIS; HYDROPHOBICITY; IC 50; NONHUMAN; OXIDATION; POSITRON EMISSION TOMOGRAPHY; PROTEIN BLOOD LEVEL; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; REVIEW; SUMOYLATION; TISSUE DISTRIBUTION; TRANSCRIPTION REGULATION; UBIQUITINATION; UNSPECIFIED SIDE EFFECT; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; DRUG DESIGN; METABOLISM;

ANIMALS; DRUG DESIGN; HUMANS; MOLECULAR STRUCTURE; ORGANOMETALLIC COMPOUNDS; RECEPTORS, ESTROGEN; SELECTIVE ESTROGEN RECEPTOR MODULATORS; STEROIDS;

EID: 67949112815     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986709788453050     Document Type: Review

References (95)

1. Parkin, D.M.; Bray, F.; Ferlay, J.; Pisani, P. Global cancer statistics. A Cancer J. Clin., 2002, 55, 74.
2. http://www.rxlist.com/top200.htm
3. Katzenellenbogen, B.S.; Katzenellenbogen, J.A. Estrogen receptor transcription and transactivation Estrogen receptor alpha and estrogen receptor beta: Regulation by selective estrogen receptor modulators and importance in breast cancer. Breast Cancer Res., 2000, 2, 335.
4. Lin, H.M.; Zhao, L.; Cheng, S.Y. Cyclin D1 is a ligand-independent co-repressor for thyroid hormone receptors. J. Biol. Chem., 2002, 277, 28733.
5. Klinge, C.M. Estrogen receptor interaction with co-activators and co-repressors. Steroids, 2000, 65, 227.
6. Delaunay, F.; Pettersson, K.; Tujague, M.; Gustafsson, J.A. Functional differences between the amino-terminal domains of estrogen receptors alpha and beta. Mol. Pharmacol., 2000, 58, 584
7. Likhite, V.S.; Stossi, F.; Kim, K.; Katzenellenbogen, B.S.; Katzenellenbogen, J.A. Kinase-specific phosphorylation of the estrogen receptor changes receptor interactions with ligand, deoxyribonucleic acid, and coregulators associated with alterations in estrogen and tamoxifen activity. Mol. Endocrinol., 2006, 20, 3120.
8. Miller, W.R. in Estrogen and Breast Cancer, Medical Intelligence Unit R. G. Landes Company and Chapman and Hall, 1996.
9. Jensen, H.I.; Jacobson, H.I. Biological Activities of Steroids in Relation to Cancer, Academic Press: New York, 1960.
10. Jurisson, S.; Berning, D.; Jia, W.; Ma, D. Coordination compounds in nuclear medicine. Chem. Rev., 1993, 93, 1137.
11. Ming, L.-J. Structure and function of "metalloantibiotics". Med. Res. Rev., 2003, 23, 697.
12. Clarke, M.J.; Zhu, F.; Frasca, D.R. Non-platinum chemotherapeutic metallopharmaceuticals. Chem. Rev. 1999, 99, 2511
13. Voigt, W.; Dietrich, A.; Schmoll, H.-J. Cisplatin und seine Analoga. Pharm. Unserer Zeit, 2006, 35, 135.
14. Kweekel, D.M.; Gelderblom, H.; Guchelaar, H.-J. Pharmacology of oxaliplatin and the use of pharmacogenomics to individualize therapy. Cancer Treat. Rev., 2005, 31, 90.
15. Verhaar-Langereis, M.J.; Zonnenberg, B.A.; de Klerk, J.M.H.; Blijham, G.H. Radioimmunodiagnosis and therapy. Cancer Treatment Rev., 2000, 26, 3.
16. Danielsen, M. Structure and Function of the Glucocorticoid Receptor. Academic Press: London, 1991.
17. Predki, P.F.; Sarkar, B. Effect of replacement of zinc finger zinc on estrogen receptor DNA interactions. J. Biol. Chem., 1992, 267, 5842.
18. Medici, N.; Minucci, S.; Nigro, V.; Abbondanza, C.; Armetta, I.; Molinari, A.M.; Puca, G.A. Metal-binding sites of the estradiol receptor from calf uterus and their possible role in the regulation of receptor function. Biochemistry, 1989, 28, 212.
19. Smith, D.E.; Kronenberg, M.S. Effects of copper on cytoplasmic and nuclear-binding of 17-beta-estradiol in the rat uterus. Biol. Reprod., 1984, 31, 531.
20. Maaroufi, Y.; Hardouze, A.B.; LeClercq, G. Decrease of hormone binding capacity of estrogen receptor by calcium. J. Receptor Signal Transduct. Res., 1997, 17, 833.
21. Flower, M.A. Targeted radiotherapy review meeting. Br. J. Radiol., 1997, 70, 875.
22. Gandolfi, O.; Blum, J.; Mandelbaum-Shavit, F. Antitumor steroidal cis-platinum(II) ortho-catecholato conjugates - preliminary evaluation on breast cancer MCF-7 cells. Inorg. Chim. Acta, 1984, 91, 257.
23. Altman, J.; Castrillo, T.; Beck, W.; Bernhardt, G.; Schönenberger, H. Metal-complexes with biologically important ligands. 62 Platinum(II) complexes of 3-(2-aminoethoxy)estrone and 3-(2-aminoethoxy)-estradiol. Inorg. Chem., 1991, 30, 4085.
24. Georgiadis, M.P.; Haroutounian, S.A.; Chondros, K.P. Synthesis and biological studies of steroidal cis-platinum(II) complexes. Inorg. Chim. Acta, 1987, 138, 249.
25. Gagnon, V.; St-Germain, M.-E.; Descoteaux, C.; Provencher-Mandeville, J.; Parent, S.; Mandal, S.K.; Asselin, E.; Berube, G. Biological evaluation of novel estrogen-platinum(II) hybrid molecules on uterine and ovarian cancers-molecular modeling studies. Bioorg. Med. Chem. Lett., 2004, 14, 5919.
26. Perron, V.; Rabouin, D.; Asselin, E.; Parent, S.; C.-Gaudreault, R.; Berube, G. Synthesis of 17 beta-estradiol-linked platinum(II) complexes and their cytocidal activity on estrogen-dependent and -independent breast tumor cells. Bioorg. Chem., 2005, 33, 1
27. Provencher-Mandeville, J.; Descoteaux, C.; Mandal, S.K.; Leblanc, V.; Asselin, E.; Berube, G. Synthesis of 17 beta-estradiol-platinum(II) hybrid molecules showing cytotoxic activity on breast cancer cell lines. Bioorg. Med. Chem. Lett., 2008, 18, 2282.
28. Barnes, K.R.; Kutikov, A.; Lippard, S.J. Synthesis, characterization, and cytotoxicity of a series of estrogen-tethered platinum(IV) complexes. Chem. Biol., 2004, 11, 557.
29. He, Q.; Liang, C.H.; Lippard, S.J. Steroid hormones induce HMG1 overexpression and sensitize breast cancer cells to cisplatin and carboplatin. Proc. Natl. Acad. Sci. USA, 2000, 97, 5768.
30. Huang, J.-C.; Zamble, D.B.; Reardon, J.T.; Lippard, S.J.; Sancar, A. HMG-domain proteins specifically inhibit the repair of the major DNA adduct of the anticancer drug cisplatin by human excision nuclease. Proc. Natl. Acad. Sci. USA, 1994, 91, 10394.
31. Chau, K.Y.; Lam, H.Y.P.; Lee, K.L.D. Estrogen treatment induces elevated expression of HMG1 in MCF-7 cells. Exp. Cell Res., 1998, 241, 269.
32. Giandomenico, C.M.; Abrams, M.J.; Murrer, B.A.; Vollano, J.F.; Rheinheimer, M.I.; Weyer, S.B.; Bossard, G.E.; Higgins, J.D. Carboxylation of kinetically inert platinum(IV) hydroxy complexes - an entree into orally-active platinum(IV) antitumor agents. Inorg. Chem., 1995, 34, 1015.
33. Alvarez-Valdez, A.; Perez, J.M.; Lopez-Solera, I.; Lannegrand, R.; Continente, J.M.; Amo-Ochoa, P.; Camazon, M.J.; Solans, X.; Font-Bardia, M.; Navarro-Ranninger, C. Preparation and characterization of platinum(II) and (IV) complexes of 1,3-diaminepropane and 1,4-diaminebutane: Circumvention of cisplatin resistance and DNA interstrand cross-link formation in CH1cisR ovarian tumor cells. J. Med. Chem., 2002, 45, 1835.
34. Jackson, A.; Davis, J.; Pither, R.J.; Rodger, A.; Hannon, M.J. Estrogen-derived steroidal metal complexes: Agents for cellular delivery of metal centers to estrogen receptor-positive cells. Inorg. Chem., 2001, 40, 3964.
35. Hannon, M.J.; Green, P.S.; Fisher, D.M.; Derrick, P.J.; Beck, J.L.; Watt, S.J.; Ralph, S.F.; Sheil, M.M.; Barker, P.R.; Alcock, N.W.; Price, R.J.; Sanders, K.J.; Pither, R.; Davis, J.; Rodger, A. An estrogen-platinum terpyridine conjugate: DNA and protein binding and cellular delivery. Chem. Eur. J., 2006, 12, 8000
36. Amouri, H.; Vessieres, A.; Vichard, D.; Top, S.; Gruselle, M.; Jaouen, G. Syntheses and affinities of novel organometallic-labeled estradiol derivatives - a structure affinity relationship. J. Med. Chem., 1992, 35, 3130.
37. Gabano, E.; Cassino, C.; Bonetti, S.; Prandi, C.; Colangelo, D.; Ghiglia, A.; Osella, D. Synthesis and characterisation of estrogenic carriers for cytotoxic Pt(II) fragments: Biological activity of the resulting complexes. Org. Biomol. Chem., 2005, 3, 3531.
38. Schobert, R.; Bernhardt, G.; Biersack, B.; Bollwein, S.; Fallahi, M.; Grotemeier, A.; Hammond, G.L. Steroid conjugates of dichloro(6-aminomethylnicotinate)platinum(II): Effects on DNA, sex hormone binding globulin, the estrogen receptor, and various breast cancer cell lines. ChemMedChem., 2007, 2, 333.
39. Hartinger, C.G.; Hann, S.; Koellensperger, G.; Sulyok, M.; Groessl, M.; Timerbaev, A.R.; Rudnev, A.V.; Stingeder, G.; Keppler, B.K. Interactions of a novel ruthenium-based anticancer drug (KP1019 or FFC14a) with serum proteins - significance for the patient. Int. J. Clin. Pharmacol. Ther., 2005, 43, 583.
40. Tinoco, A.D.; Earnes, E.V.; Valentine, A.M. Reconsideration of serum Ti(IV) transport: Albumin and transferrin trafficking of Ti(IV) and its complexes. J. Am. Chem. Soc., 2008, 130, 2262.
41. Siiteri, P.K.; Murai, J.T.; Hammond, G.L.; Nisker, J.A.; Raymoure, W.J.; Kuhn, R.W. The serum transport of steroid hormones. Recent Prog. Horm. Res., 1982, 38, 457.
42. Mendel, C.M. The free hormone hypothesis - a physiologically based mathematical model. Endocr. Rev., 1989, 10, 232
43. (a) Catalano, M.G.; Frairia, R.; Boccuzzi, G.; Fortunati, N. Sex hormone-binding globulin antagonizes the anti-apoptotic effect of estradiol in breast cancer cells. Mol. Cell. Endocrinol., 2005, 230, 31.
44. (b) Catalano, M.G.; Comba, A.; Fazzari, A.; Benedusi-Pagliano, E.; Sberveglieri, M.; Revelli, A.; Massobrio, M.; Frairia, R.; Fortunati, N. Sex steroid binding protein receptor (SBP-R) is related to a reduced proliferation rate in human breast cancer. Breast Cancer Res. Treat., 1997, 42, 227.
45. Ng, K.-M.; Catalano, M.G.; Pinós, T.; Selva, D. M.; Avvakumov, G.V.; Munell, F.; Hammond, G.L. Evidence that fibulin family members contribute to the steroid-dependent extravascular sequestration of sex hormone-binding globulin. J. Biol. Chem., 2006, 281, 15853.
46. Hammes, A.; Andreassen, T.K.; Spoelgen, R.; Raila, J.; Hubner, N.; Schulz, H.; Metzger, J.; Schweigert, F.J.; Luppa, P.B.; Nykjaer, A.; Willnow, T.E. Role of endocytosis in cellular uptake of sex steroids. Cell, 2005, 122, 751.
47. Westphal, U. Steroid-Protein Interactions II. Springer-Verlag: Berlin, Germany, 1986.
48. Renoir, J.M.; Mercier-Bodard, C.; Baulieu, E.E. Hormonal and immunological aspects of the phylogeny of sex steroid binding plasma protein. Proc. Natl. Acad. Sci. USA, 1980, 77, 4578.
49. D'Amato, R.J.; Lin, C.M.; Flynn, E.; Folkman, J.; Hamel, E. 2-Methoxyestradiol, an endogenous mammalian metabolite, inhibits tubulin polymerization by interacting at the colchicine site. Proc. Natl. Acad. Sci. USA, 1994, 91, 3964.
50. Grishkovskaya, I.; Avvakumov, G.V.; Hammond, G.L.; Catalano, M.G.; Muller, Y.A. Steroid ligands bind human sex hormone-binding globulin in specific orientations and produce distinct changes in protein conformation. J. Biol. Chem., 2002, 277, 32086
51. Kim, E.; Croy, R.G.; Essigmann, J.M. Design of programmable platinum antitumor agents for breast and ovarian cancers. J. Biol. Inorg. Chem., 2007, 12(Suppl 1), S36.
52. (a) Osella, D.; Nervi, C.; Galeotti, F.; Cavigiolio, G.; Vessieres, A.; Jaouen, G. The ferrocenylethynyl unit: A stable hormone tag. Helv. Chim. Acta, 2001, 84, 3289.
53. (b) Top, S.; El Hafa, H.; Vessieres, A.; Quivy, J.; Vaissermann, J.; Hughes, D.W.; McGlinchey, M.J.; Mornon, J.-P.; Thoreau, E.; Jaouen, G. Rhenium carbonyl complexes of beta-estradiol derivatives with high affinity for the estradiol receptor: An approach to selective organometallic radiopharmaceuticals. J. Am. Chem. Soc., 1995, 117, 8372.
54. (c) Top, S.; El Hafa, H.; Vessieres, A.; Huche, M.; Vaissermann, J.; Jaouen, G. Novel estradiol derivatives labeled with Ru, W, and Co complexes. Influence on hormone-receptor affinity of several organometallic groups at the 17 alpha position. Chem. Eur. J., 2002, 8, 5241.
55. (d) Ferber, B.; Top, S.; Vessieres, A.; Welter, R.; Jaouen, G. Synthesis of optically pure o-formylcyclopentadienyl metal complexes of 17 alpha-ethynylestradiol. Recognition of the planar chirality by the estrogen receptor. Organometallics, 2006, 25, 5730.
56. Raffy, Q.; Ricoux, R.; Mahy, J.-P. Synthesis of a new estradiol-iron metalloporphyrin conjugate used to build up a new hybrid biocatalyst for selective oxidations by the 'Trojan horse' strategy. Tetrahedron Lett., 2008, 49, 1865.
57. De Lauzon, S.; Rajkowski, K.M.; Cittanova, N. Investigation of a 17-beta-estradiol-monoclonal antiestradiol antibody-binding mechanism using dilute solutions of organic solvents. J. Steroid Biochem. Mol. Biol., 1994, 48, 225.
58. Yang, X.-B.; Feng, J.; Zhang, J.; Zhang, Z.-W.; Lin, H.-H.; Zhou, L.-H.; Yu, X.-Q. Synthesis, DNA binding and cleavage activities of the copper(II) complexes of estrogen-macrocyclic polyamine conjugates. Bioorg. Med. Chem., 2008, 16, 3871.
59. (a) Skaddan, M.B.; Wust, F.R.; Katzenellenbogen, J.A. Synthesis and binding affinities of novel re-containing 7 alpha-substituted estradiol complexes: Models for breast cancer imaging agents. J. Org. Chem., 1999, 64, 8108.
60. (b) Skaddan, M.B.; Wust, F.R.; Jonson, S.; Syhre, R.; Welch, M.J.; Spies, H.; Katzenellenbogen, J.A. Radiochemical synthesis and tissue distribution of Tc-99m-labeled 7α-substituted estradiol complexes. Nuc. Med. Biol., 2000, 27, 269.
61. Wüst, F.; Skaddan, M.B.; Leibnitz, P.; Spies, H.; Katzenellenbogen, J.A.; Johannsen, B. Synthesis of novel progestin-rhenium conjugates as potential ligands for the progesterone receptor. Bioorg. Med. Chem., 1999, 7, 1827.
62. Ramesh, C.; Bryant, B.; Nayak, T.; Revankar, C.M.; Anderson, T.; Carlson, K.E.; Katzenellenbogen, J.A.; Sklar, L.A.; Norenberg, J.P.; Prossnitz, E.R.; Arterburn, J.B. Linkage effects on binding affinity and activation of GPR30 and estrogen receptors ER alpha/beta with tridentate pyridin-2-yl hydrazine tricarbonyl-Re/Tc-99m(I) chelates. J. Am. Chem. Soc., 2006, 128, 14476.
63. (a) Filardo, E.J.; Quinn, J.A.; Bland, K.I.; Frackelton, A.R. Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF. Mol. Endocrin., 2000, 14, 1649.
64. (b) Thomas, P.; Pang, Y.; Filardo, E.J.; Dong, J. Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells. Endocrinology, 2005, 146, 624.
65. (c) Revankar, C.M.; Cimino, D.F.; Sklar, L.A.; Arterburn, J.B.; Prossnitz, E.R. A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science, 2005, 307, 1625
66. Prossnitz, E.R.; Arterburn, J.B.; Edwards, B.S.; Sklar, L.A.; Oprea, T.I. Steroid-binding G-protein-coupled receptors: New drug targets for old ligands. Exp. Opin. Drug Discov., 2006, 1, 137.
67. Mikola, H.; Sundell, A.-C.; Hanninen, E. Labeling of estradiol and testosterone alkyloxime derivatives with a europium chelate for time-resolved fluoroimmunoassays. Steroids, 1993, 58, 330.
68. Lo, K.K.-W.; Lee, T.K.-M.; Lau, J.S.-Y.; Poon, W.-L.; Cheng, S.-H. Luminescent biological probes derived from ruthenium(II) estradiol polypyridine complexes. Inorg. Chem., 2008, 47, 200.
69. Lo, K.K.-W.; Zhang, K.Y.; Chung, C.-K.; Kwok, K.Y. Synthesis, photophysical and electrochemical properties, and protein-binding studies of luminescent cyclometalated Iridium(III) bipyridine estradiol conjugates. Chem. Eur. J., 2007, 13, 7110.
70. Ohmichi, M.; Tasaka, K.; Kurachi, H.; Murata, Y. Molecular mechanism of action of selective estrogen receptor modulator in target tissues. Endocrine J., 2005, 52, 161.
71. (a) Kowalski, K.; Vessieres, A.; Top, S.; Jaouen, G.; Zakrzewski, J. Modification of the Cp' ring in the ferrocifen precursor and its influence on the recognition by the estrogen receptor. Tetrahedron Lett., 2003, 44, 2749.
72. (b) Plazuk, D.; Vessieres, A.; Le Bideau, F.; Jaouen, G.; Zakrzewski, J. Synthesis of benzyl- and benzhydrylferrocenes via Friedel-Crafts alkylation of ferrocene. Access to ferrocenyl bisphenols with high affinities for estrogen receptors. Tetrahedron Lett., 2004, 45, 5425.
73. (c) Top, S.; Tang, J.; Vessieres, A.; Carrez, D.; Provot, C.; Jaouen, G. Ferrocenyl hydroxytamoxifen: A prototype for a new range of oestradiol receptor site-directed cytotoxics. Chem. Commun., 1996, 955.
74. Afrasiabi, Z.; Sinn, E.; Padhye, S.; Dutta, S.; Padhye, S.; Newton, C.; Anson, C.E.; Powell, A.K. Transition metal complexes of phenanthrenequinone thiosemicarbazone as potential anticancer agents: synthesis, structure, spectroscopy, electrochemistry and in vitro anticancer activity against human breast cancer cell-line, T47D. J. Inorg. Biochem., 2003, 95, 306.
75. Schertl, S.; Hartmann, R.W.; Batzl-Hartmann, C.; Spruß, T.; Maucher, A.; von Angerer, E.; Schiller, C.D.; Schneider, M.R.; Gust, R.; Schönenberger, H. Platinum(II) complexes interfering with testicular steroid biosynthesis: Drugs for the therapy of advanced or recurrent prostate cancers? Preclinical studies. J. Cancer Res. Clin. Oncol., 2007, 133, 153.
76. Schneider, M.R.; Schiller, C.D.; Humm, A.; Spruß, T.; Schönenberger, H.; Amselgruber, W.; Sinowatz, F. 1,2-Bis(2,6-dichloro-4-hydroxyphenyl) ethylenediaminedichloroplatinum(II) - an endocrine-active platinum complex with a specific prostatic tumor-inhibiting activity. Prostate, 1989, 15, 135.
77. Corey, E.; Quinn, J.E.; Emond, M.J.; Buhler, K.R.; Brown, L.G.; Vesella, R.L. Inhibition of androgen-independent growth of prostate cancer xenografts by 17 beta-estradiol. Clin. Cancer Res., 2002, 8, 1003.
78. Joseph, I.B.J.K.; Isaacs, J.T. Macrophage role in the anti-prostate cancer response to one class of antiangiogenic agents. J. Natl. Cancer Inst., 1998, 90, 1648.
79. (a) Schertl, S.; Hartmann, R.W.; Batzl-Hartmann, C.; Bernhardt, G.; Spruß, T.; Beckenlehner, K.; Koch, M.; Krauser, R.; Schlemmer, R.; Gust, R.; Schönenberger, H. [1,2-bis(2,6-difluoro-3-hydroxyphenyl)ethylenediamine]platinum(II) complexes, compounds for the endocrine therapy of breast cancer - mode of action I: Antitumor activity due to the reduction of the endogenous estrogen level. Arch. Pharm. Pharm. Med. Chem., 2004, 337, 335.
80. (b) For the effect of meso-26 on breast cancer cells see: Schlemmer, R.; Spruß, T.; Bernhardt, G.; Schönenberger, H. Does [meso-1,2-bis(2,6-dichloro-4- hydroxyphenyl)ethylenediamine] dichloroplatinum (II) act as an immune response modifier? IV. Inhibition of the proliferation-increasing effect of progressively growing MXT-M-3,2 breast cancer on phagocytes by the title compound. Arch. Pharm. Pharm. Med. Chem., 2001, 334, 309.
81. Gust, R.; Niebler, K.; Schönenberger, H. N-Ethyl- and [N,N′-diethyl-1,2-bis (2,6-difluoro-3-hydroxyphenyl) ethylenediamine]dichloroplatinum(II): Structure and cytotoxic/estrogenic activity in breast cancer cells. J. Med. Chem., 2005, 48, 7132.
82. Schobert, R.; Bernhardt, G.; Biersack, B.; Bollwein, S. Unpublished results.
83. (a) Bielawski, K.; Bielawska, A.; Sosnowska, K.; Miltyk, W.; Winnicka, K.; Palka, J. Novel amidine analogue of melphalan as a specific multifunctional inhibitor of growth and metabolism of human breast cancer cells. Biochem. Pharmacol., 2006, 72, 320
84. (b) Fukazawa, H.; Noguchi, K.; Murakami, Y.; Uehara, Y. Mitogen-activated protein/extracellular signal-regulated kinase kinase (MEK) inhibitors restore anoikis sensitivity in human breast cancer cell lines with a constitutively activated extracellular-regulated kinase (ERK) pathway. Mol. Cancer Ther., 2002, 1, 303
85. O'Brian, C.A.; Liskamp, R.M.; Solomon, D.H.; Weinstein, I.B. Inhibition of protein kinase-C by tamoxifen. Cancer Res., 1985, 45, 2462.
86. (b) Kanter-Lewensohn, L.; Girnita, L.; Girnita, A.; Dricu, A.; Olsson, G.; Leech, L.; Nilsson, G.; Hilding, A.; Wejde, J.; Brismar, K.; Larsson, O. Tamoxifen-induced cell death in malignant melanoma cells: possible involvement of the insulin-like growth factor-1 (IGF-1) pathway. Mol. Cell Endocrine., 2000, 165, 131.
87. Top, S.; Kaloun, E.B.; Vessieres, A.; Leclerq, G.; Laios, I.; Ourevitch, M.; Deuschel, C.; McGlinchey, M.J.; Jaouen, G. Tamoxifen derivatives for delivery of the antitumoral (DACH)Pt group: Selective synthesis by McMurry coupling, and biochemical behaviour. ChemBioChem, 2003, 4, 754.
88. Mull, E.S.; Sattigeri, V.J.; Rodriguez, A.L.; Katzenellenbogen, J.A. Aryl cyclopentadienyl tricarbonyl rhenium complexes: Novel ligands for the estrogen receptor with potential use as estrogen radiopharmaceuticals. Bioorg. Med. Chem., 2002, 10, 1381.
89. Brzozowski, A.M.; Pike, A.C.W.; Dauter, Z.; Hubbard, R.E.; Bonn, T.; Engström, O.; Öhman, L.; Greene, G.L.; Gustafsson, J.-A.; Carlquist, M. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature, 1997, 389, 753.
90. Top, S.; Kaloun, E.B.; Vessieres, A.; Laios, I.; Leclerq, G.; Jaouen, G. The first titanocenyl dichloride moiety vectorised by a selective estrogen receptor modulator (SERM). Synthesis and preliminary biochemical behaviour. J. Organomet. Chem., 2002, 643-644, 350.
91. Labrie, F. Future perspectives of selective estrogen receptor modulators used alone and in combination with DHEA. Endocrine-related Cancer, 2006, 13, 335.
92. Roncaglioni, A.; Benfenati, E. In silico-aided prediction of biological properties of chemicals: Oestrogen receptor-mediated effects. Chem. Soc. Rev. 2008, 37, 441.
93. Sun, P.; Sehouli, J.; Denkert, C.; Mustea, A.; Könsgen, D.; Koch, I.; Wei, L.; Lichtenegger, W. Expression of estrogen receptor-related receptors, a subfamily of orphan nuclear receptors, as new tumor biomarkers in ovarian cancer cells. J. Mol. Med., 2005, 83, 457.
94. Zhou, H.-B.; Collins, M.L.; Gunther, J.R.; Comninos, J.S.; Katzenellenbogen, J. A. Bicyclo 2.2.2 octanes: Close structural mimics of the nuclear receptor-binding motif of steroid receptor coactivators. Bioorg. Med. Chem. Lett., 2007, 17, 4118.
95. Massaad-Massade, L.; Massaad, C.; Legendre, F.; Bas, V.; Chottard, J.-C.; Beaune, P.; Barouki, R. A single d(GpG) cisplatin adduct on the estrogen response element decreases the binding of the estrogen receptor. FEBS Lett., 2000, 466, 49.